Color keeps GSK generic off the market

Share this article:
Color keeps GSK generic off the market
Sandoz's AirFluSal Forspiro

A purple casing is keeping Sandoz from being able to market its generic of GlaxoSmithKline's COPD drug Advair in Germany.

The Wall Street Journal reports that GSK filed a preliminary injunction against the Novartis generics division because the Sandoz inhaler for its AirFluSal Forspiro inhaler is purple, just like the inhaler for GSK's Advair (known as Seretide and Viani), claiming unfair competition.

"Glaxo says it believes customers recognize the color purple as indicating its own product and Forspiro's appearance could lead to confusion among patients, pharmacists and healthcare providers,” reports the WSJ.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.

India's Marck gets FDA Warning Letter

Inspectors of Marck Biosciences found an array of problems during a October-November 2013 inspection, including mold near a sterile area that was so bad "the room had 'partially caved in.'"

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.